EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan

Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Clinical Drug Investigation · 2024

DOI: 10.1007/s40261-024-01352-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, 2024. Verfasst von Teppei Hagino und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School, Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba, 270-1694, Japan. teppei-hagino@nms.ac.jp. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Eczema, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: MEXT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsEczemaHeterocyclic Compounds, 3-RingHumansJapanSeverity of Illness IndexDouble-Blind MethodPruritusTreatment Outcome

Substanzen

upadacitinibJanus Kinase InhibitorsHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Dermatology, Nippon Medical School, Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba, 270-1694, Japan. teppei-hagino@nms.ac.jp.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.
  • Department of Dermatology, Nippon Medical School, Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba, 270-1694, Japan.

Förderung

  • MEXT

Zitieren

APA

Hagino, T., Hamada, R., Yoshida, M., Saeki, H., Fujimoto, E., & Kanda, N. (2024). Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01352-4

Vancouver

Hagino T, Hamada R, Yoshida M, Saeki H, Fujimoto E, Kanda N. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan. Clinical Drug Investigation. 2024. doi:10.1007/s40261-024-01352-4

BibTeX
@article{Hagino2024,
  author = {Hagino, Teppei and Hamada, Risa and Yoshida, Mai and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan},
  journal = {Clinical Drug Investigation},
  year = {2024},
  doi = {10.1007/s40261-024-01352-4}
}
Kostenlos starten →